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Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal
tumors and usually presented with locally advanced and distant metastasis disease,
which prevent curative resection or treatments. In this regard, we considered
identifying molecular subtypes associated with clinicopathological factor as prognosis
factors to stratify PDAC for appropriate treatment of patients.
Results: In this study, we identified three molecular subtypes which were significant
on survival time and metastasis. We also identified significant genes and enriched
pathways represented for each molecular subtype. Considering R0 resection patients
included in each subtype, metastasis and survival times are significantly associated
with subtype 1 and subtype 2.
Conclusions: We observed three PDAC molecular subtypes and demonstrated that
those subtypes were significantly related with metastasis and survival time. The study
may have utility in stratifying patients for cancer treatment.
Background
PDAC has high propensity for local invasion and early development of metastasis,
resulting poor long-term survival [1-3]. Moreover, more than 80% of patients are diag-
nosed at advanced stages and their survival times are extremely shorter than those
from other solid tumors [1]. According to recent reports [4,5], PDAC is the 4th most
common cancer accompanied by 4th highest mortality rate among gastrointestinal tract
cancers in the U.S.A. [4,5]. In contrast with outcome of treatments improving in other
solid cancers, prognosis of pancreatic cancer still remains low and unchanged for the
past 15 years. At present, overall median survival of PDAC patients is 13 months, and
median survival after R0 resection is 23 months [3].
Conventionally known PDAC factors are difficult to suggest prognostic factors of
pancreatic cancer, because those factors are in the depth of invasion, lymph node
metastasis, and histologic differentiation. Presently, the prognosis and treatment plan
for patients are determined according to these prognostic factors and American joint
committee on cancer (AJCC) tumor staging [6]. However, patients with the same
AJCC stage or other pathologic prognostic factors have various clinical courses and
prognosis. In addition, their responses to chemotherapy vary widely; therefore,
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established treatment plan and prognosis prediction with molecular datasets should
extend patients’ survival time. In the same context, identification of molecular subtypes
would contribute the comprehensive understanding of a genomic transition and cancer
development [1]. Unlike other solid tumor studies, identifying the molecular subtypes
of PDAC has been frustrating due to lack of tumor specimens for such studies [2]. We
attempted to resolve this problem with surgically collected 106 samples from the Seoul
National University Hospital. Identification of molecular subtypes provides stratifica-
tion of patients by their cancer genome context.
Materials and methods
Materials
From 2009 to 2011, 106 patients underwent surgery for pancreatic ductal adenocarci-
noma at Seoul National University Hospital approved by the Institutional Review
Board. Clinicopathologic data were prospectively collected in electronic medical record
form. The patients had a postoperative follow-up for at least 1 year. All of the patients
had fresh frozen tissue and acceptable quality of DNA extracted from the tissue. After
the operation, 5x5 mm sized tumor tissues were immediately collected from surgical
specimens and stored in a -70°C liquid nitrogen tank until DNA extraction. Routinely
processed 4-µm thick paraffin-embedded sections from the same lesion were stained
with hematoxylin and eosin, then submitted for histologic examination. Concentration
of the DNA was calculated with spectrophotometer, and the DNA purity and integrity
were evaluated by optical density 260/280 ratio for quality control. We selected 96
samples, which passed quality control test.
Methods
Survival after resection is associated with many clinical factors such as stage, grade
(cell differentiation), and metastasis [7,8]. We extracted 20,219 unique genes out of
22,077 genes (from 33,297 of probe ID) for each sample. All microarray gene expres-
sion data sets were transformed to log2 scale. To identify PDAC molecular subtypes,
we used consensus clustering methods [9] and non-negative matrix factorization meth-
ods (NMF) [10]. Here we mainly discussed NMF clustering algorithm; NMF method is
using factorizing expression profiles based on positive matrices decomposition. Main
concept of NMF is using the mRNA expression matrix A(n: genes by m: subjects)
following:
A ∼ WH
where A is n by mmatrix, the size of matrixW is n by k, and the size of H is k by m. k is
the column length ofW and same as the row length of H. The number of clusters is k as
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The components of matrix W and H are called metagenes, which contain sample
and gene information of A, since those components are related with all of the gene
expression levels of samples. Moreover, components of H contain all gene expression
information as well as samples’ clustering patterns. More details are explained in [10].
To perform NMF algorithm, we first downloaded Multi experimental view (MeV) [11]
from http://www.tm4.org/ Then we used the following parameters and options for
MeV’s setting: divergence is used for cost function (eq 1) with update rules (eq 2, 3),
exponential scale is used for adjusting given data, and maximum iteration is at 1000.
Cophenetic correlation coefficient [12]c provides a scalar value measuring robustness
across the consensus matrix, by using microarray expression levels for each cluster.
The cophenetic correlation coefficients are obtained as 0, being poorly-clustered, to 1,











Where Yij = |Yi − Yj | is a distance between two observations; i, j, and Zij is the den-
drogrammatic distance of subtype distance between model Zi and Zj. The highest value
of the cophenetic correlation coefficient determines the optimal number of clusters.
Results
Demographics and pathologic characteristics of the ninety six pancreatic cancer
patients are summarized in Table 1. The mean age of resection for the patients was
65.2 years and the ratio of male to female was 1:1.04. The median for follow up after
resection was 14.3 months, and fifty eight patients had recurrence at the end of their
follow-ups. R0 resection rate of the patients was 79.2%. Most patients, 94.8%, were
diagnosed at Stage II.
Table 1 Demographics and pathologic characteristics of the study subjects
N = 96
Age (mean ± SD) 65.2 ± 9.1
Sex (M:F) 1:1.04
Operation
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Identifying 3 molecular subtypes of PDAC
We performed NMF with cophenetic coefficients testing size of cluster from 2 to 4.
The resulting cophenetic correlation coefficient for clusters 2, 3, and 4 were 0.896,
0.994, and 0.979, respectively. Figure 1 shows the results of NMF and cophenetic cor-
relation coefficients. Since the maximum peak of the cophenetic correlation coeffi-
cients’ plot determines the optimal number of subtypes, selecting 3 cluster provides
the best separations compared to the rest. Therefore, we further analyzed these 3
groups. In the case of three subtypes, the number of samples for each cluster is 43, 45,
and 8 with 27, 22, and 4 censored samples, successively.
Analysis and comparison between determined subtypes
We plotted the Kaplan-Meier survival curve using IBM SPSS statistic 20 in Figure 2.
The median of overall survival was 23 months, while the median survival times are
37.6, 19.2, and 13.8 months for each subtypes 1, 2, and 3, respectively. The p-value
from the log-rank test comparing subtypes 1 and 2 is 0.001, comparing subtypes 1
and subtype 3 is 0.008, while the p-value between subtypes 2 and 3 is 0.374. Consis-
tently, longer surviving patients have much less metastasis disease according to
Table 2. Although subtypes 2 and 3 are clearly separated in NMF, with cophenetic
correlation coefficients 0.97, Kaplan-Meier curve is not statistically significant; this
might be due to the small sample size of subtype 3. Comparison results of clinico-
pathologic characteristics according to 3 molecular subtypes are summarized in
Table 2.
The mean age of each cluster is 66.3 (± 8.1), 64.2 (± 10.3), and 64.8 (± 7.4) for sub-
type 1, subtype 2, and subtype 3, respectively. R0 resection rate was significantly higher
in subtype 1 (p = 0.029) than in subtypes 2 and 3.
Tumor size tended to be larger (p = 0.073) and endovenous invasion rate lower (p =
0.070) in subtype 3 than in subtypes 1 and 2. Recurrence rate inclined to be lower in
Table 1 Demographics and pathologic characteristics of the study subjects (Continued)






Stage IA 3 (3.1%)
Stage IB 0
Stage IIA 41 (42.7%)
Stage IIB 50 (52.1%)
Stage III 1 (1.0%)
Stage IV 1 (1.0%)
Histologic differentiation
Well differentiated 3 (3.1%)
Moderately differentiated 84 (87.5%)
Poorly differentiated 9 (9.4%)
Perineural invasion 83 (86.5%)
Endolymphatic invasion 39 (40.6%)
Endovenous invasion 25 (26.0%)
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subtype 1 than in subtypes 2 and 3 (p = 0.091) and distant metastasis rate tended to be
higher in subtype 2 than in subtypes 1 and 3 (p = 0.022).
Especially, when comparing only subtype 1 with subtype 2, the ratio of R0 was signif-
icantly higher in subtype 1 than in subtype 2 (90.7% vs. 68.9%, p = 0.016), and distant
metastasis ratio to non-metastasis was significantly higher in subtype 2 than in subtype
1 (66.7% vs. 39.5%, p = 0.018). The prognosis of subtype 2 is significantly worse than
Figure 1 Plot of NMF performances and Cophenetic coefficients correlation. (a) k = 2 (b) k = 3 and
(c) k = 4 where k is number of clusters. (d) Illustration of Cophenetic coefficients for number of clusters.
Figure 2 Kaplan-Meier survival curve. Kaplan-Meier survival curve comparing survival of individuals with
subtype 1 (blue), subtype 2 (green), and subtype 3 (orange) with 0.001 p-value by log-rank statistics test.
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subtype 1 (median 19.2 vs. 37.6 months, p = 0.001). However, average age, sex, and
local invasion are not significant among subtypes with p >0.5. The result implies that
these molecular subtypes are useful for poor-prognosis markers for cancer treatment,
by triggering the target genes.
Analysis and comparison of subtype 1 and subtype 2 restricted to R0 resection patients
We also analyzed sub-clinicopathologic characters restricted to R0 resection between
39 subtype 1 patients and 31 subtype 2 patients. Metastasis is significant between sub-
type 1 (n = 15, 38.5%) and subtype 2 (n = 21, 67.7%) with p-value = 0.018. We plotted
Kaplan-Meier curve with R0 resection survival time demonstrating that prognosis is
significantly poor in subtype 2 (median 22.4 mo) compared to subtype 1 (median not
reached) with p = 0.024 in Figure 3. Disease free survival was significantly lower in
subtype 2 than that of subtype 1 (median 10.9 vs. 20.6 months, p = 0.010) in Figure 4.
Identifying enriched pathway between subtype 1 and subtype 2
For functional assessment of our subtype identification, we performed gene set enrich-
ment analysis [13] to get enriched pathway information for subtype 1 and subtype 2.
Since sample size of subtype 3 is much smaller than that of the other two, we excluded
subtype 3 in this analysis. In this step of the analysis, we used KEGG pathway with 200
individuals downloaded from the molecular signatures data base (MSigDB) [13] with
1,000 permutations. The results of top nine pathways ordered by their absolute nor-
malized enriched score in each subtype, are shown in Table 3. FDR q-value of all
enriched pathways is less than 0.25.
Table 2 Clinicopathologic characteristics according to 3 molecular subtypes
Subtype 1 (n = 43) Subtype 2 (n = 45) Subtype 3 (n = 8) P-value
Age (mean ± SD) 66.3 ± 8.1 64.2 ± 10.3 64.8 ± 7.4 0.570
Male gender 22 (51.2%) 20 (44.4%) 5 (62.5%) 0.585
Tumor size (cm) 3.0 ± 1.0 3.4 ± 1.1 3.6 ± 0.8 0.073
R status 0.029
R0 39 (90.7%) 31 (68.9%) 6 (75.0%)
R1, R2 4 (9.3%) 14 (31.1%) 2 (25.0%)
AJCC Stage 0.304
Stage IIA 19 (44.2%) 21 (46.7%) 1 (12.5%)
Stage IIB 21 (48.8%) 22 (48.9%) 7 (87.5%)
Histologic differentiation 0.417
Well differentiated 1 (2.3%) 1 (2.2%) 1 (12.5%)
Moderately differentiated 39 (90.7%) 38 (84.4%) 7 (87.5%)
Poorly differentiated 3 (7.0%) 6 (13.3%) 0
Perineural invasion 35 (81.4%) 40 (88.9%) 8 (100%) 0.298
Endolymphatic invasion 17 (39.5%) 18 (40.0%) 4 (50.0%) 0.690
Endovenous invasion 9 (20.9%) 16 (35.6%) 0 0.070
Adjuvant chemotherapy 37 (86.0%) 43 (95.6%) 7 (87.5%) 0.215
Gemcitabine 21 (48.8%) 30 (66.7%) 5 (62.5%) 0.267
5-FU 10 (23.3%) 10 (22.2%) 1 (12.5%) 0.936
Unknown 6 (14.0%) 3 (6.7%) 1 (12.5%)
Recurrence 21 (48.8%) 32 (71.1%) 5 (62.5%) 0.091
Local 10 (23.3%) 11 (24.4%) 2 (25.0%) 1.0
Distant 17 (39.5%) 30 (66.7%) 3 (37.5%) 0.022
Kim et al. BioMedical Engineering OnLine 2014, 13(Suppl 2):S5
http://www.biomedical-engineering-online.com/content/13/S2/S5
Page 6 of 11
The enriched pathways of subtype 2 were related with fatal disease pathways includ-
ing pancreatic cancer, renal cell carcinoma, and chronic myeloid leukemia. On the
other hand, the enriched pathways of subtype 1 were related to immune system, such
as hematopoietic cell lineage, cytokine-cytokine receptor interaction, and calcium sig-
naling pathway. The findings of enriched pathways in Table 3 are consistent with sur-
vival analysis in Figure 1.
Identifying significant biomarkers for each subtype
More importantly, we identified differentially expressed genes between subtypes using
significant analysis of microarray (SAM) [14]. Significant genes specific to each group
were chosen one versus the rest, which implies one group (subtype 1) is compared to
the other two groups (subtypes 2 and 3). Boxplot with Kruskal-Wallis test supported
our clustering in Figure 5. We selected top 20 genes with 0 q-value ordered in fold-
change for up-regulated genes in case subtypes, in Table 4. 10 bold genes were also
found by Collisson [2] as PDAC assigner genes among 62. Interestingly, the 9 high-
lighted genes in subtype 3, on Korean pancreatic subtypes, are found at exocrine-like
subtype assigner genes in three identified subtypes in Figure 1 (a) of previous study
[2]. However, the proportion of sample size of subtype 3 from total Korean PDAC
Figure 3 Kaplan-Meier survival curve for R0 resection with survival.
Figure 4 Kaplan-Meier survival curve for R0 resection with disease free survival.
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patients are much smaller than that of Exocrine-like subtype from GSE15471 data sets
nm2344-S2 in [2], which are 8% and 36%, respectively. This excessive difference,
between the two datasets of equal subtypes, require an extended study in the future.
Validation of the results
For the validation study of our findings, we used an independent dataset GSE28735
[15] downloaded from Gene expression omnibus. GSE28735 consists of 45 PDAC sam-
ples. We extracted all biomarkers in Table 4 from each validation sample and imple-
mented NMF from rank 2 to rank 4. The highest cophenetic coefficient is 0.975 when
rank is 3 in Figure 6. The best result of implementing Kaplan-Meier survival analysis
was to compare subtype 3 versus rest, which yielded p-value 0.198. The p-values are
0.384 and 0.522 for the tests comparing subtype 1 versus rest and subtype 2 versus
rest, respectively. The significant biomarkers matched 9 out of 13 for subtype 2 and 13
out of 20 for subtype 3 in Table 4.
Conclusions
It is an important issue to identify molecular subtypes for stratifying PDAC patients
depending on clinicopathologic factors and molecular gene expression. These identified
molecular subtypes can be utilized for stratifying patients into their appropriate treat-
ment groups. In this regard, we used total of 96 PDAC samples, and identified 3
Table 3 Enriched pathways of subtype 1 and subtype 2
Enriched pathway in Subtype 2 (poor-
prognosis)
Enriched pathway in Subtype 1 (good-prognosis)
HSA03010_RIBOSOME HSA04080_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION
HSA00190_OXIDATIVE_PHOSPHORYLATION HSA04060_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION









Figure 5 Boxplots of Kruskal-Wallis test using overexpressed genes in each subtype. Boxplots of
Kruskal-Wallis test for comparing 3 subtypes (a) using overexpressed genes of subtype 1, (b) using
overexpressed genes of subtype 2, and (c) using overexpressed genes of subtype 3.
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molecular subtypes which were significantly related to clinicopathologic factors such as
metastasis, tumor size, residual, and survival time. The results consistently demonstrate
that poor prognosis is significantly related to metastasis. We also identified enriched
pathways for poor-prognosis and good-prognosis related to fatal diseases and immune
system, respectively, in Table 3. Moreover, we suggested gene markers represented for
each subtype to use in PDAC stratification. We also considered the restricted to R0
resection samples in each subtype. Prognosis was significantly worse in subtype 2 than
in subtype 1. Disease free survival rate was significantly lower in subtype 2 compared
to subtype 1. In addition, 13 out of 22 over-expressed genes of subtype 3 in our























Figure 6 Plot of NMF performance k = 3 (a), and cophenetic coefficients of validation data sets (b).
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findings are also found in exocrine-like subtypes in previous study [2], but further
study is required on the radically short survival time for Korean specific biomarker for
PDAC subtypes using larger sample size.
Nevertheless, our findings have some limitation for being applied to the patients
directly. Even though we selected the significant gene sets using strong machine learn-
ing tools, and successfully clustered 3 classes in validation data sets, we still need a
further investigation for validation of following up patients and/or using new data sets.
At this moment, such high quality gene expression data sets including R0 resection,
metastasis and survival time information are not available in public.
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